The role of emicizumab in acquired hemophilia A

2.

Leone

MC

,

Canovi

S

,

Pilia

A

, et al.

Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine

.

Thromb Res

.

2022

;

211

(

5

):

60

-

62

.

doi:10.1016/j.thromres.2022.01.017

.

3.

Happaerts

M

,

Vanassche

T.

Acquired hemophilia following COVID-19 vaccination: case report and review of literature

.

Res Pract Thromb Haemost

.

2022

;

6

(

6

):

e12785

.

doi:10.1002/rth2.12785

.

4.

Knoebl

P

,

Marco

P

,

Baudo

F

, et al.

Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

.

J Thromb Haemost

.

2012

;

10

(

4

):

622

-

631

.

doi:10.1111/j.1538-7836.2012.04654.x

.

5.

Zeitler

H

,

Goldmann

G

,

Marquardt

N

,

Ulrich-Merzenich

G.

Long term outcome of patients with acquired haemophilia–a monocentre interim analysis of 82 patients

.

Atheroscler Suppl

.

2013

;

14

(

1

):

223

-

228

.

doi:10.1016/j.atherosclerosissup.2012.10.033

.

6.

Kruse-Jarres

R

,

St-Louis

J

,

Greist

A

, et al.

Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

.

Haemophilia

.

2015

;

21

(

2

):

162

-

170

.

doi:10.1111/hae.12627

.

7.

Tiede

A

,

Collins

P

,

Knoebl

P

, et al.

International recommendations on the diagnosis and treatment of acquired hemophilia A

.

Haematologica

.

2020

;

105

(

7

):

1791

-

1801

.

doi:10.3324/haematol.2019.230771

.

8.

Baudo

F

,

Collins

P

,

Huth-Kühne

A

, et al.

Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry

.

Blood

.

2012

;

120

(

1

):

39

-

46

.

doi:10.1182/blood-2012-02-408930

.

9.

Holstein

K

,

Liu

X

,

Smith

A

, et al.

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

.

Blood

.

2020

;

136

(

3

):

279

-

287

.

doi:10.1182/blood.2019003639

.

10.

Kruse-Jarres

R

,

Kempton

CL

,

Baudo

F

, et al.

Acquired hemophilia A: updated review of evidence and treatment guidance

.

Am J Hematol

.

2017

;

92

(

7

):

695

-

705

.

doi:10.1002/ajh.24777

.

11.

Tiede

A

,

Klamroth

R

,

Scharf

RE

, et al.

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

.

Blood

.

2015

;

125

(

7

):

1091

-

1097

.

doi:10.1182/blood-2014-07-587089

.

12.

Oldenburg

J

,

Mahlangu

JN

,

Kim

B

, et al.

Emicizumab prophylaxis in hemophilia A with inhibitors

.

N Engl J Med

.

2017

;

377

(

9

):

809

-

818

.

doi:10.1056/NEJMoa1703068

.

13.

Mahlangu

J

,

Oldenburg

J

,

Paz-Priel

I

, et al.

Emicizumab prophylaxis in patients who have Hemophilia A without inhibitors

.

N Engl J Med

.

2018

;

379

(

9

):

811

-

822

.

doi:10.1056/NEJMoa1803550

.

14.

Muto

A

,

Yoshihashi

K

,

Takeda

M

, et al.

Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A

.

Blood

.

2014

;

124

(

20

):

3165

-

3171

.

doi:10.1182/blood-2014-07-585737

.

15.

Shima

M

,

Hanabusa

H

,

Taki

M

, et al.

Factor VIII–mimetic function of humanized bispecific antibody in hemophilia A

.

N Engl J Med

.

2016

;

374

(

21

):

2044

-

2053

.

doi:10.1056/nejmoa1511769

.

16.

Young

G

,

Callaghan

M

,

Dunn

A

,

Kruse-Jarres

R

,

Pipe

S.

Emicizumab for hemophilia A with factor VIII inhibitors

.

Expert Rev Hematol

.

2018

;

11

(

11

):

835

-

846

.

doi:10.1080/17474086.2018.1531701

.

17.

Mahlangu

J.

Emicizumab for the prevention of bleeds in hemophilia A

.

Expert Opin Biol Ther

.

2019

;

19

(

8

):

753

-

761

.

doi:10.1080/14712598.2019.1626370

.

18.

Callaghan

MU

,

Negrier

C

,

Paz-Priel

I

, et al.

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

.

Blood

.

2021

;

137

(

16

):

2231

-

2242

.

doi:10.1182/blood.2020009217

.

19.

Knoebl

P

,

Thaler

J

,

Jilma

P

,

Quehenberger

P

,

Gleixner

K

,

Sperr

WR

.

Emicizumab for the treatment of acquired hemophilia A

.

Blood

.

2021

;

137

(

3

):

410

-

419

.

doi:10.1182/blood.2020006315

.

20.

Thomas

VM

,

Abou-Ismail

MY

,

Lim

MY

.

Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature

.

Haemophilia

.

2022

;

28

(

1

):

4

-

17

.

doi:10.1111/hae.14450

.

21.

Jacqueline

N.

Poston

KA-B

,

von Drygalski

A

, et al.

Emicizumab for the treatment of acquired hemophilia A: a multicenter US case series

.

Blood

.

2021

;

138

:

496

.

doi:10.1182/blood-2021-148040

.

22.

Shima

M

,

Amano

K

,

Ogawa

Y

, et al.

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

.

J Thromb Haemost

.

2023

;

21

(

3

):

534

-

545

.

doi:10.1016/j.jtha.2022.10.004

.

23.

Pipe

SW

,

Shima

M

,

Lehle

M

, et al.

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

.

Lancet Haematol

.

2019

;

6

(

6

):

e295

-

e305

.

doi:10.13039/100007013

.

24.

Batty

P

,

Moore

G

,

Platton

S

, et al.

Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A

.

Thromb Haemost

.

2015

;

114

(

10

):

804

-

811

.

doi:10.1160/th14-12-1062

.

25.

Kizilocak

H

,

Marquez-Casas

E

,

Malvar

J

,

Carmona

R

,

Young

G.

Comparison of bypassing agents in patients on emicizumab using global hemostasis assays

.

Blood

.

2019

;

134

(

suppl 1

):

904

.

doi:10.1182/blood-2019-132050

.

26.

Turecek

PL

,

Romeder-Finger

S

,

Apostol

C

, et al.

A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE

.

Haemophilia

.

2016

;

22

(

6

):

957

-

965

.

doi:10.1111/hae.13001

.

27.

Tiede

A

,

Hofbauer

CJ

,

Werwitzke

S

, et al.

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

.

Blood

.

2016

;

127

(

19

):

2289

-

2297

.

doi:10.1182/blood-2015-09-672774

.

28.

Levy

GG

,

Asikanius

E

,

Kuebler

P

,

Benchikh El Fegoun

S

,

Esbjerg

S

,

Seremetis

S.

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program

.

J Thromb Haemost

.

2019

;

17

(

9

):

1470

-

1477

.

doi:10.13039/100007013

.

29.

Schmitt

C

,

Emrich

T

,

Chebon

S

, et al.

Low immunogenicity of emicizumab in persons with haemophilia A

.

Haemophilia

.

2021

;

27

(

6

):

984

-

992

.

doi:10.1111/hae.14398

.